Market Overview

Piper Jaffray Reiterates Overweight Rating, $97 PT for DaVita

Share:
Related DVA
Worst Performing Industries For August 19, 2016
Earnings Scheduled For August 8, 2016
DaVita HealthCare: How Bad The Medicaid/Medicare RFI Really Is - And Why You Can Still Hold The Stock (Seeking Alpha)

In a report published earlier today, Piper Jaffray & Co. reiterated its Overweight rating and $97.00 price target for DaVita, Inc. (NYSE: DVA), related to DaVita's recently-announced acquisition of HealthCare Partners.

Piper Jaffray went on to say “DVA is paying approximately $4.42 billion to acquire HealthCare Partners which is about 1.8x TTM revenue and 8.4x TTM EBITDA. The transaction will be financed with approximately 9.38 MM shares of DVA common stock with an estimated value of ~$758 MM, with the remainder coming from available cash, additional borrowings under DVA's senior credit facility and additional debt financing. DVA does expect to amend its senior credit facility. Assuming modest 5% revenue growth in 2012 and 2013 from HealthCare Partners and consistent operating margins of about 20% we believe the transaction could add ~$1.46 in 2013.”

DaVita, Inc. closed on Friday at $80.81.

Latest Ratings for DVA

DateFirmActionFromTo
Aug 2016JP MorganMaintainsNeutral
Mar 2016BernsteinMaintainsMarket Perform
Sep 2015JP MorganInitiates Coverage onNeutral

View More Analyst Ratings for DVA
View the Latest Analyst Ratings

Posted-In: Piper Jaffray & Co.Analyst Color Reiteration Analyst Ratings

 

Related Articles (DVA)

View Comments and Join the Discussion!